|
Match
|
Document |
Document Title |
|
|
7387776 |
Human monoclonal antibodies against CD30
Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of...
|
|
|
7381411 |
Aglyco products and methods of use
Glycoconjugates, therapeutic compositions containing the glycoconjugates and therapeutic methods of using the glycoconjugates are disclosed. In particular, peptide constituents of aglyco 10B, which...
|
|
|
7371379 |
Dosages for treatment with anti-ErbB2 antibodies
The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or...
|
|
|
7368428 |
Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
Methods and compositions for restoring sensitivity to the antitumorigenic effects of antiestrogen therapy and/or cytotoxic therapy and inducing cell apoptosis are provided. Contacting tumor cells...
|
|
|
7361341 |
Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the treatment of cancers and other...
|
|
|
7354762 |
Method for producing CE7-specific redirected immune cells
Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular...
|
|
|
7335748 |
RG1 antibodies and uses thereof
The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and...
|
|
|
7332582 |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation...
|
|
|
7326415 |
Antibodies to non-functional P2X7 receptor
The present invention provides antibodies that specifically bind to P2X 7 receptors and distinguish between functional and non-functional P2X7 receptors, pharmaceutical compositions and kits...
|
|
|
7323170 |
Anti-CD80 antibodies
The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from...
|
|
|
7321026 |
Framework-patched immunoglobulins
Framework (FR)-patching is a novel approach to modify immunoglobulin for reducing potential immunogenicity without significant alterations in specificity and affinity. Unlike previous described...
|
|
|
7320791 |
Monoclonal antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
A novel anti-polyethylene glycol monoclonal antibody and its preparation are disclosed. Such an antibody can be used for determining polyethylene glycol concentration in vitro or accelerating the...
|
|
|
7319139 |
TAG-72 specific CH2 domain deleted antibodies
Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may...
|
|
|
7318924 |
Antibodies against cancer
An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell...
|
|
|
7314623 |
Methods and compositions for modulating T helper (Th) cell development and function
Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e.g., human IL-21, activity or level.
|
|
|
7314622 |
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic...
|
|
|
7306801 |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one...
|
|
|
7288252 |
Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment...
|
|
|
7288249 |
Antibodies for cancer therapy and diagnosis
The present application describes a method for making antibodies which can be used for cancer diagnosis or therapy. The application also discloses a method for identifying an antigen which is...
|
|
|
7282567 |
Monoclonal antibody hPAM4
This invention relates to monovalent and multivalent, monospecific antibodies and to multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding...
|
|
|
7265209 |
CE7-specific chimeric T cell receptor
Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular...
|
|
|
7261892 |
Methods for diagnosis and treatment of epithelial-derived cancers
The present invention relates to the use of a polypeptide (CD27L) for diagnosis of epithelial-related cancers, in particular kidney cancer e.g. renal cell cancer and colorectal cancer, e.g. colon...
|
|
|
7255858 |
Enhancing the efficacy of immunotherapies by supplementing with complement
The present invention is directed to a composition and method for enhancing the complement-mediated cytotoxicity of therapeutic antibodies for their target cells (i.e. those cells displaying the...
|
|
|
7253263 |
Complementarity determining region-grafted antibody against ganglioside GD3 and derivative of antibody against ganglioside GD3
The present invention relates to a human CDR-grafted antibody against ganlioside GD3 (hereinafter referred to “GD3”), derivatives of an anti-GD3 antibody and cytokine, and use for treatment and...
|
|
|
7252994 |
Human DR4 antibodies and uses thereof
Human Death Receptor 4 (DR4) antibodies are provided. The human DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis...
|
|
|
7241568 |
Anti-fibroblast growth factor-8 monoclonal antibody
A method for preventing or treating a disease, comprising administering to human or animal in need of such prevention or treatment an effective amount of a monoclonal antibody which specifically...
|
|
|
7238786 |
Monoclonal antibody cPAM4
This invention relates to monovalent and multivalent, monospecific antibodies and to monovalent and multivalent, multispecific antibodies. One embodiment of these antibodies has one or more...
|
|
|
7238785 |
RS7 antibodies
This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more...
|
|
|
7232888 |
Antibodies against tumor surface antigens
The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity...
|
|
|
7226596 |
Compositions and methods for the treatment of tumors
The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the...
|
|
|
7217799 |
Antibodies that recognize the 85P1B3 protein useful in treatment and detection of cancer
A novel gene (designated 85P1B3) and its encoded protein are described. While 85P1B3 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers...
|
|
|
7217796 |
Neutralizing human anti-IGFR antibody
The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing...
|
|
|
7208151 |
Tweak receptor agonists as anti-angiogenic agents
The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are...
|
|
|
7204982 |
Compositions and methods for treatment and detection of multiple cancers
The invention provides a method for inhibiting proliferation of cancer cells, as well as methods for detecting and treating various cancers, including cancer of the brain, lung, breast, prostate...
|
|
|
7202346 |
Antibodies to non-shed Muc1 and Muc16, and uses thereof
The present invention relates to antibodies, antibody fragments, conjugates of antibodies and antibody fragments with cytotoxic agents, and hybridomas producing the antibodies and antibody...
|
|
|
7198787 |
Method of killing target cells in harvested cell populations with one or more immuno-toxins
A method for killing unwanted target cells in a cell population comprising nucleated cells harvested from peripheral blood, or CD-34+ or similar early progenitor cells selected from the above...
|
|
|
7192586 |
Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
Methods and compositions for treating, preventing, or diagnosing epidermal or dermal disorders, e.g., psoriasis, are disclosed. The methods and compositions of the invention use binding agents,...
|
|
|
7192585 |
CD80 specific antibodies
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
7189825 |
Cancerous disease modifying antibodies
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer...
|
|
|
7189824 |
Tumor vessel endothelial cell-binding monoclonal antibodies
A monoclonal antibody which recognizes an antigen of a molecular weight of 40 kD or 80 kD on the surface of tumor vessel endothelial cells, hybridomas producing the monoclonal antibody,...
|
|
|
7189397 |
Cytotoxicity mediation of cells evidencing surface expression of CD44
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease...
|
|
|
7179899 |
Composite antibodies of humanized human subgroup IV light chain capable of binding to TAG-72
Novel composite and humanized anti-TAG-72 monoclonal antibodies, antibody fragments, and derivatives thereof using human subgroup IV kappa light chain framework regions.
|
|
|
7169390 |
Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation
Methods and compositions are disclosed that are useful for the prevention and/or treatment of cancer, angiogenesis, and inflammation. The beneficial effects of the compositions and methods are...
|
|
|
7166286 |
Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for prophylaxis and detection of cancers
The present invention relates to monoclonal antibody H11 and antigen binding fragments that specifically bind to the antigen recognized by H11, the C-antigen. The C-antigen is found specifically on...
|
|
|
7160858 |
Methods and compositions for inhibiting angiogenesis
Methods for inhibiting angiogenesis in endothelial cells and selectively inducing apoptosis in endothelial cells via compounds which binds annexin II are provided. These compounds and methods for...
|
|
|
7153508 |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
7151169 |
Specific binding members for TGFβ1
The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID...
|
|
|
7151164 |
Anti-CD20 antibodies and fusion proteins thereof and methods of use
The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the...
|
|
|
7150871 |
Treatment of acute lung injury, fibrosis and metastasis with antagonists of αvβ6
Methods and compositions comprising antagonists of αvβ6 are provided for the treatment of acute lung injury fibrosis.
|
|
|
7147855 |
GIPs, a family of polypeptides with transcription factor activity that interact with goodpasture antigen binding protein
The present invention provides isolated GPBP-interacting 90 and 130 kDa polypeptides, and portions thereof (GIP90/130 polypeptides), antibodies to the GIP90/130 polypeptides, and pharmaceutical...
|